BIBLIOGRAFÍA 1) Büttner P, Garbe C, Bertz J, Burg G, dHoedt B, Drepper H, y col. Primary cutaneous melanoma. Optimized cutoff of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995: 75 (10): 2499-506. 2) Dennis LK, White E, Lee JA, Kristal A, McKnight B, Odland R Constitutional factors and sun exposure in relation to nevi: a population-based cross-sectional Study. Am J Epidemiol 1996, 143(3): 248-56 3) Eller MS, Ostrom K, Gilchrest BA. DNA damage enhances melanogenesis. Proc Natl Acad Sci USA. 1996-93(3): 1087-92. 4) Rehman I, Takata M, Wu YY, Rees JL. Genetic change in actinic keratoses. Oncogene. 1996; 12(12): 2483-90. 5) Enschede CW, Happle R. Xeroderma Pigmentosum: Welding as a Risk Factor. Melanoma Res 1993; 3:17. 6) Carli P, Biggeri A, Giannotti B. Malignant melanoma in Italy: risks associated with common and clinically atypical melanocytic nevi. Dermatology Clinic II, University of florence, Italy. J Am Acad Dermatol 1995; 32(5) Pt 1: 734-9. 7) Westerdahl J, Olsson H, Ingvar C. At what age do sunburn episodes play a Crucial role for the development of malignant melanoma [published erratum appears in Fur J Cancer 1995: 31A(2): 287] Eur J Cancer 1994; 30A(11): 1647-54. 8) Autier P, Doré JF, Lejeune F Koelmel KF, Geffeler 0, Hille P y col. Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: an EORTC multicenter case-control study in Belgium, France and Germany. EORTC Melanoma Cooperative Group. Int J Cancer 1994; 58(6): 809-13. 9) Bataille V, Bishop JA, Sasieni P, Swerdlow AJ, Pinney E, Griffiths K y col . Risk of Cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 1996; 73(12): 1605-11. 10) Grulich AE, Bataille V, Swerdlow AJ, Newton Bishop JA, Cuzick J, Hersey P y col. Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case control study in New South Wales, Australia. hit J Cancer 1996; 67(4): 485-91. 11) Pieger E. Overall and Site-Specific Risk of Malignant Melanoma Associated with High Nevus Counts (Meeting Abstract). Melanoma Res 1993; 3: 36. 12) Fritschi L, Siemiatycki J. Melanoma and Occupation: Results of a Case-Control Study. Occup Environ Med 1996; 53 (3): 168-73. 13) Claus G. Primary Cutaneous Melanoma. Cancer May 15, 1995, 75 (10): 2489. 14) Claus G. Primary Cutaneous Melanoma-Prognostic Anatomic Location. J Cancer May 15, 1995; 75 (10): 2490-7. 15) Balch CH, Hougeton AN. Histopathology of Malignant Melanoma and Its Precursor Lesions. Cutaneous Melanoma. 1992: 224-61. 16) Taylor CH, Cote RJ. Inmunohistology the skin: Melanoma, Intermediate Filament. Immunomicroscopy: A Diagnostic Tool for the Surgical Pathologist 1994, chapter 12. págs: 318-41. 17) Nirecka J. Comparative Distribution of SIN Protein and Antigen HMB-45 in various types of melanomas and Nevi. Pol J Pathol. 1995, 46 (3): 167-72. 18) Kikuchi A, Shimizu H, Nishikawa T. Epidermal Melanocytes in normal and Tyrosinase-Negative Oculocutaneous Albinism Fetuses. Arch Dermatol Res 1995; 287 (6): 529-33. 19) Schreiner TU, Lischka G, Schaumburg Lever G. Langerhans Cells in Skin Tumors. Arch Dermatol 1995; 131 (2): 187-90. 20) Brinkschmidt C. Immunohistochemical Demonstration of Chromogranin A, B, and secretoneurm in Merckel Cell Carcinoma of the Skin. Applied Immunohistochemistry 1995; 3 (1): 3-44. 21) Robbins P. The P53 Tumor Suppressor Gene and the C-erb B-2/HER-2 Oncogene in Breast Cancer. Application of Molecular Biology to Diagnostic Pathology. XX International Congress of the International Academy of Pathology Oct. 1994. 22) Yamamoto M. Expression of the P53 Protein in Malignant Melanoma as Prognostic Indicator. Arch Dermatol Res 1995; 287 (2): 146-51. 23) Linden MD. Evaluation of anti-P53 Antibody Staining Immunoreactivity in Benign Tumors and Nonneoplastic Tissues. Applied Immunohistochemistry 1995; 3 (4): 232-8.
|
